

Primary Research on Clinical Outcomes and Perceptions of CAR-T Therapy

Objective Outcome and Response Analysis
Survey of 50 Healthcare Professionals in the US and Europe



Sample Size
50 Respondents



Regions
USA (30) & Europe (20)



Methodology
Online Questionnaire

Research Overview & Methodology



Study design, respondent profile, and baseline engagement metrics

Research Objectives

- ✓ **Evaluate Awareness:** Assess clinical usage and familiarity with CAR-T therapy among professionals.
- ✓ **Assess Outcomes:** Analyze perceived treatment efficacy and patient survival outcomes.
- ✓ **Identify Challenges:** Pinpoint key barriers regarding accessibility, cost, and safety.
- ✓ **Review Safety:** Understand common adverse effects and management strategies.

Methodology

Online questionnaire survey conducted with verified healthcare professionals.

Sample Composition

Total Respondents

N = 50

Professional Roles

- Oncologists
- Hematologists
- Immunotherapy Researchers
- Oncology Nurses
- Clinical Trial Coordinators

Regional Distribution



Baseline Stats

92%

Familiar with CAR-T
46 of 50 respondents

72%

Clinical Involvement
Direct treatment or research

i High baseline awareness indicates strong market penetration in surveyed regions.

Awareness and Professional Involvement


Q1 Are you familiar with CAR-T therapy?



● Yes (92%) ● No (8%)

High Baseline Awareness: 92% of respondents are familiar with CAR-T therapy, indicating strong market penetration and knowledge among oncology professionals in the US and Europe.


Q2 Have you been involved in CAR-T therapy treatment or research?



Active Adoption: Nearly 72% of respondents have direct clinical or research involvement, reflecting the transition of CAR-T from experimental to established clinical practice.


Indications Treated and Perceived Effectiveness

Q3 Which cancers do you most commonly see treated with CAR-T therapy?



Dominance in Blood Cancers: 76% of usage is concentrated in Leukemia and Lymphoma. This aligns with clinical evidence showing strong responses in B-cell malignancies, while solid tumor adoption remains low (8%).


Q4 How effective do you consider CAR-T therapy compared to conventional treatments?



High Efficacy Perception: 90% of respondents rate CAR-T as moderately to highly effective. This perception matches clinical trial data showing response rates up to 70% in certain hematologic indications.


Barriers and Future Positioning

Q5 What are the biggest challenges of CAR-T therapy?



Cost & Infrastructure: High cost (36%) is the single largest barrier. Combined with limited availability and complex manufacturing, operational and financial hurdles outweigh clinical safety concerns.

Q8 Will CAR-T therapy become a first-line treatment in the future?



Future Expansion: A strong majority (64%) believe CAR-T will advance to first-line settings, suggesting high confidence in its evolving role despite current barriers.

Patient Outcomes and Adverse Effects


Q6 What patient outcomes have you observed after CAR-T therapy?



- Complete Remission (36%)
- Partial Response (34%)
- Stable Disease (18%)
- No Response (12%)

Significant Clinical Benefit: 70% of patients experience either complete remission or partial response, validating the therapy's high efficacy profile in real-world settings.

Q7 What adverse effects are most common?



Primary Safety Concern: Cytokine Release Syndrome (CRS) remains the most frequent complication (44%), followed by neurological toxicity, highlighting the need for specialized management.

Key Findings

Strategic insights from the survey of 50 healthcare professionals



92%

High Awareness

Near-universal familiarity among oncologists and researchers in US & EU markets, establishing a strong foundation for adoption.



Top Usage

Hematologic Focus


Clinical application is currently concentrated in **Leukemia** and **Lymphoma**, consistent with approved indications.



~70%

Clinical Response

Perceived response rates align closely with clinical trial data, reinforcing professional confidence in efficacy.



Primary Barriers

High cost and complex **infrastructure** requirements remain the most significant hurdles preventing wider scalability and patient access.



Future Outlook

The majority of respondents anticipate CAR-T therapy will move to **earlier lines of treatment**, expanding beyond last-resort settings.



Thank You

Do you have any questions?

+91-959-915-8047

info@sperresearch.com

<https://www.sperresearch.com>

Corporate Office:

#303-304, Tower B, Noida One, Sector 62, Noida, India